The Increase in Gastrointestinal Diseases and Changing Lifestyles with a shift in Dietary Habits are Driving the Growth of the Global Nausea Medicine Market at a CAGR of 7.83% during the Forecast Period

Pune, India, February 2022, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global Nausea Medicine Market.

Market Highlights

The Nausea Medicine Market is expected to reach USD 1.54 Billion by 2030 at 7.83% CAGR during the forecast period 2023-2030

Nausea medicines are therapeutic agents that are effective against nausea and vomiting. Nausea and vomiting are the symptoms of several medical conditions such as motion sickness, dizziness, pregnancy, emotional stress, and food poisoning. These medicines are often used to treat the side effects of other medications including opioid analgesics, chemotherapy, and general anesthetics.

The growing cases of cancer rise in gastrointestinal diseases, and increasing geriatric population, sedentary lifestyle and unhealthy diet, are driving the global nausea medicine market. However, a high preference for home remedies is expected to hamper the growth of this market during the forecast period. Nevertheless, collaborations between large drug manufacturing companies and small companies are likely to set a lucrative opportunity for the growth of this market in the near future.

Segment Analysis

Global Nausea Medicine Market has been segmented By Type, Mode of Administration, Indication, and Distribution Channel.

The nausea medicine market, on the basis of type, has been segmented into antagonists, cannabinoids, antihistamines, and others. The nausea medicine market, based on the mode of administration, is divided into oral, intravenous, and others. The nausea medicine market, based on indication, is divided into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. The nausea medicine market, based on distribution channel, is divided into hospital/retail pharmacies and online.     

Regional Analysis

Global Nausea Medicine Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to hold the largest share of the global nausea medicine market during the assessment period. The presence of major pharmaceutical manufacturers, rising prevalence of gastrointestinal diseases such as GERD and cancer cases supports the Americas market growth. For instance, the American Cancer Society had stated that around 1,762,450 new cancer cases were diagnosed in 2019. Also, the prevalence of nausea is increasing among school-going children, further pushing the market growth upward. Europe established substantial growth in the market owing to the boost in the biopharmaceutical sector in the European region, improving economies, high disposable income per individual, and increased healthcare spending is anticipated to propel the demand for nausea medicine during the forecast period. Asia-Pacific is estimated to be the fastest-growing regional market due to growing awareness about diseases, government support to improve the healthcare sector, and rising geriatric population. For instance, according to United Nations ESCAP, the Asia-Pacific region is experiencing population aging at an unprecedented pace, with the number of older persons expected to more than double, from 535 million in 2015 to about 1.3 billion in 2050. The nausea medicine market in the Middle East & Africa is expected to witness gradual growth. The growth of this market is attributed to the increasing number of cancer population and rising disposable income countries such as Qatar, the UAE, and Saudi Arabia.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Nausea Medicine Market Research Report

Key Players

MRFR recognizes the following companies as the Key Players in the Global Nausea Medicine Market— Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and others.

Key Findings of the Study

• Global Nausea Medicine Market was valued at USD 89 Million in 2019 and is expected to register a CAGR of 7.83% during the assessment period of 2019 to 2027


• The Americas accounted for the largest share of the global nausea medicine market


• Based on the type, the antagonists segment is expected to register the highest CAGR of 8.02% during the forecast period


• Based on mode of administration, the oral segment is expected to register the highest CAGR of 8.04% during the forecast period


• Based on indication, oncology segment accounted for a larger market share of 39.84% in 2019


• Based on distribution channel, hospital/retail pharmacies held the largest market share of 66.08% of the nausea medicine market in 2019